Portfolio Category: Pharmaceuticals

MyOR prevents a range of health issues using innovative, holistic solutions that combine predictive, noninvasive, monitoring technologies and customized products to help the body help itself. Our monitoring technologies leverage skin-sensing techniques and data science tools to gain new insight into systemic health and reveal the inner workings of your body. With these technologies in hand, MyOR customizes care solutions to prevent health conditions from developing.

Ayana Pharma develops liposome-based treatments for cancer. Ayana was formed to leverage the benefits of the anticancer drug Doxil, an FDA-approved liposomal nanodrug that has been used in the treatment of ovarian cancer, metastatic breast cancer, AIDS-related Kaposi’s sarcoma, and multiple myeloma. Co-founded by one of Doxil’s co-inventors, Professor Yechezkel Barenholz from the Hebrew University, the company is working to expand its treatment uses and efficacy while making it more readily available to address a range of conditions. Ayana has completed fundraising to support an abbreviated new drug application (ANDA), filing, and commercialization.

LipoMedix is a development-stage privately held company focused on the development of an innovative, safe and effective cancer therapy based on liposome delivery. The Company was established in order to advance the pharmaceutical and clinical development of a patented new chemical entity prodrug of mitomycin-C and its efficient delivery in liposomes to cancer-affected target organs. This formulation known as Promitil  – Pegylated Liposomal Mitomycin-C Prodrug (PL-MLP) – overcomes the problems associated with mitomycin-C toxicity and turn it into a state-of-the-art anti-cancer drug that will potentially become the therapy of choice in a variety of cancers, especially those derived from the gastrointestinal tract (stomach, pancreas, colorectal). The inventor and scientific founder, of LipoMedix is Prof. Alberto Gabizon of the Hebrew University – Shaare Zedek Medical Center who is also the co-inventor and co-developer of Doxil, (the first FDA-approved nano-drug in cancer therapy). As co-developer of Doxil® Prof. Gabizon is one of the few scientists intimately familiar with the successful development & commercialization process of liposomal drugs.

Everything we do is intended to reduce post-surgical complications and help save lives. We do so by developing unique, proprietary polymers that are designed specifically to help prevent complications. Our first product, Voyager Medical Suture, addresses the post-surgical complication of Incisional Hernia, that is effecting up to 20% of every patient undergoing a Laparotomy, leading to 3.4% mortality. Our team is highly experienced and recognized in the field of wound-closure and biocompatible polymers.

Viral diseases represent a serious health threat, exemplified by the recent COVID-19 pandemic. Moreover, viral diseases, such as Dengue, West Nile, and Zika fevers exact a particularly significant toll in the developing world. Relying on the results of two decades of research, ViroBlock plans to target and exploit a particular vulnerability in the viruses that cause these diseases: ion channels. Channels are critical components of the pathogen that enable it to regulate its salinity and acidity. Consequently, inhibiting such channels is a promising and validated route to curb viral infectivity. In particular, ViroBlock developed rapid screening approaches that can identify inhibitors from thousands of chemicals in a matter of weeks. Finally, focusing the screen on a library of approved drugs (repurposing) shortens the regulatory approval time dramatically, while lowering the risk.

Tissue Dynamics bionic microtissues are three dimensional human organoids embedded with electro optical sensors that provide critical insight into human-relevant mechanisms. These proprietary physiological models are powered by unprecedented AI & automation capabilities. 

Developer of a medical navigational tool designed to reduce the length of ERCP procedure. The company’s tool helps in preventing inflammation that can be caused during the procedure if the catheter is accidentally inserted into the pancreas duct, rather than the gallbladder duct, enabling surgeons to accurately diagnose and treat patients suffering from bile duct blockage.

SpliSense is an Israel-based company focused on transformative RNA-based treatments. Our pioneering platform harnesses Antisense Oligonucleotides (ASOs) for treatment of genetic diseases such as Cystic Fibrosis and pulmonary diseases. Our innovative approach targets unmet needs in pulmonary diseases. SpliSense aims to target the root cause of the disease, to overcome specific genetic mutations and restore protein function.

Senseera’s technology ushers a new generation of liquid biopsy blood tests providing unparalleled information about disease processes in the patient’s internal organs and immune system with a single blood test. Senseera’s mission is to transform disease diagnosis and treatment and to enhance development of new therapeutics.